Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy.
- Author:
Chang-Juan TAO
1
,
2
;
Xu LIU
;
Ling-Long TANG
;
Yan-Ping MAO
;
Lei CHEN
;
Wen-Fei LI
;
Xiao-Li YU
;
Li-Zhi LIU
;
Rong ZHANG
;
Ai-Hua LIN
;
Jun MA
;
Ying SUN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; diagnosis; drug therapy; metabolism; pathology; radiotherapy; Chemoradiotherapy; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; diagnosis; drug therapy; metabolism; pathology; radiotherapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; methods; Risk Assessment; methods; Tumor Burden; Young Adult
- From:Chinese Journal of Cancer 2013;32(9):494-501
- CountryChina
- Language:English
- Abstract: The prognostic value of T category for locoregional control in patients with nasopharyngeal carcinoma (NPC) has decreased with the extensive use of intensity-modulated radiotherapy (IMRT). We aimed to develop a prognostic scoring system (PSS) that incorporated tumor extension and clinical characteristics for locoregional control in NPC patients treated with IMRT. The magnetic resonance imaging scans and medical records of 717 patients with nonmetastatic NPC treated with IMRT at Sun Yat-sen University Cancer Center between January 2003 and January 2008 were reviewed. Age, pathologic classification, primary tumor extension, primary gross tumor volume (GTV-p), T and N categories, and baseline lactate dehydrogenase (LDH) level were analyzed. Hierarchical cluster analysis as well as univariate and multivariate analyses were used to develop the PSS. Independent prognostic factors for locoregional relapse included N2-3 stage, GTV-p ≥26.8 mL, and involvement of one or more structures within cluster 3. We calculated a risk score derived from the regression coefficient of each factor and classified patients into four groups: low risk (score 0), intermediate risk (score >0 and ≤1), high risk (score >1 and ≤2), and extremely high risk (score >2). The 5-year locoregional control rates for these groups were 97.4%, 93.6%, 85.2%, and 78.6%, respectively (P < 0.001). We have developed a PSS that can help identify NPC patients who are at high risk for locoregional relapse and can guide individualized treatments for NPC patients.
